DOWNLOAD
1 min read
Putting patients at the center of a new biopharma business model
![](/sites/default/files/styles/insights_thumbnail_field_m/public/prism/ADL_Prism_2_2009_New_Biopharma.jpg,qitok=KSfqU_iB.pagespeed.ce.th3w15O_CW.jpg)
The pharmaceutical industry is suffering. Expiring patents, increasing demands from regulators and decreasing healthcare budgets are putting companies under pressure, and the industry has to walk a narrow tightrope between keeping profitability up and quickly developing attractive medications. As patients are increasingly well informed, organized and powerful, a novel approach that some companies are looking into is patient-centrism. This means integrating patient inputs in each stage of the value chain, from drug development through commercialization to lifecycle management. We carried out 50 in-depth interviews with industry experts to find out how this new model can hold the future for the bio pharma business.
![](/sites/default/files/prism/ADL_Prism_2_2009_New_Biopharma.jpg.pagespeed.ce.aFkIloQIz6.jpg)
![](/sites/default/files/styles/insights_thumbnail_field_m/public/prism/ADL_Prism_2_2009_New_Biopharma.jpg,qitok=KSfqU_iB.pagespeed.ce.th3w15O_CW.jpg)
The pharmaceutical industry is suffering. Expiring patents, increasing demands from regulators and decreasing healthcare budgets are putting companies under pressure, and the industry has to walk a narrow tightrope between keeping profitability up and quickly developing attractive medications. As patients are increasingly well informed, organized and powerful, a novel approach that some companies are looking into is patient-centrism. This means integrating patient inputs in each stage of the value chain, from drug development through commercialization to lifecycle management. We carried out 50 in-depth interviews with industry experts to find out how this new model can hold the future for the bio pharma business.